Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*

Jean Louis Vincent; Derek C. Angus; Antonio Artigas; André C. Kalil; Bruce R. Basson; Hassan H. Jamal; Gerald D. Johnson; Gordon R. Bernard

doi:10.1097/01.ccm.0000051515.56179.e1

Back

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*

Article 2003 en

Abstract

1 min read

Drotrecogin alfa (activated) demonstrated significant improvements in organ function compared with placebo in a large phase 3 clinical trial that has shown a mortality benefit in patients with severe sepsis.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2007

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus, Jeffrey D. Helterbrand, Howard Levy, Jean-François Dhainaut, Jean Louis Vincent, William L. Macias, Gordon R. Bernard

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*

Abstract

Discussion(0)

Related publications

Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis

Drotrecogin alfa (activated) in the treatment of severe sepsis

Drotrecogin alfa (activated): the treatment for severe sepsis?

Drotrecogin alfa: a new approach in the treatment of severe sepsis

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis